To determine whether targeting AKT and disrupting the interaction between EGFR and pAKTSer473 could enhance gefitinib efficacy in lung cancer cells with mt-BRG1 and wt-EGFR status, H358-BRG1-KO and parental A549 (mt-BRG1) cells were treated with gefitinib alone (2 μM or 10 μM GEF), MK2206 (0.25 μM) alone, or the combination of both drugs. This evidence concerns the gene EGFR and lung carcinoma.